» Articles » PMID: 28787694

Prevalence and Nature of Cardiovascular Disease in Methamphetamine-related Death: A National Study

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2017 Aug 9
PMID 28787694
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Methamphetamine dependence is a major public health problem. This study examined the nature, and extent, of cardiovascular disease amongst cases of methamphetamine-related death in Australia, 2009-2015.

Methods: Analysis of 894 cases of methamphetamine-related death with full autopsy reports retrieved from the National Coronial Information System.

Results: The mean age was 37.9yrs (range 15-69yrs) and 78.5% were male. A quarter (26.3%) of cases had enlarged hearts and left ventricular hypertrophy was diagnosed in 18.9%. Severe coronary artery disease was present in 19.0%, the left coronary artery being the vessel most frequently stenosed (16.6%). Replacement fibrosis (evidence of earlier ischaemic events) in the heart muscle was observed in 19.8% of cases, and cardiomyopathy was diagnosed in 5.5%. Histological evidence of hypertension was observed in 32.7% of cases. With the exception of cardiomyopathy, equally common amongst both sexes, cardiovascular disease was more common amongst males, and those aged >35yrs. Clinically significant levels of cardiovascular disease were also observed amongst cases where the cause of death was not attributed to cardiovascular disease: cardiomegaly (19.3%), left ventricular hypertrophy (14.6%), severe coronary artery disease (9.4%), replacement fibrosis (14.4%), cardiomyopathy (3.3%).

Conclusions: Cardiovascular disease was highly prevalent, despite the relatively young age of cases. With methamphetamine use increasing rapidly in major regions, cardiovascular disease and cardiovascular-related death will likely increase amongst methamphetamine users.

Citing Articles

Amphetamine use as a predictor of cardiovascular and cerebrovascular mortality and morbidity: a longitudinal cohort study of criminal justice clients.

Ahman A, Berge J, Hakansson A Front Cardiovasc Med. 2025; 12:1378833.

PMID: 39925980 PMC: 11802577. DOI: 10.3389/fcvm.2025.1378833.


Assessment of Contributing Risk Factors Leading to Heart Failure in Patients Who Are Methamphetamine Users.

To M, Savoj J, Kraft J, Chang J, Ayutyanont N, Vandeveer C Cureus. 2025; 16(12):e76479.

PMID: 39866973 PMC: 11769095. DOI: 10.7759/cureus.76479.


The impact of methamphetamine on liver injury in Iraqi male addicts.

Mohammed N, Ali Z, Mohamed A, Mirza S Toxicol Rep. 2024; 13:101806.

PMID: 39624223 PMC: 11609243. DOI: 10.1016/j.toxrep.2024.101806.


Home inotrope therapy in chronic stimulant-induced cardiomyopathy: a case series.

Joseph M, Batra S, Kamran W, Barrett K, Ebert B, Nassar A Eur Heart J Case Rep. 2024; 8(8):ytae406.

PMID: 39171134 PMC: 11336994. DOI: 10.1093/ehjcr/ytae406.


Cardiomyopathy-Associated Hospital Admissions Among Methamphetamine Users: Geographical and Social Disparities.

Al-Yafeai Z, Ali S, Brown J, Venkataraj M, Bhuiyan M, Mosa Faisal A JACC Adv. 2024; 3(7):100840.

PMID: 39130045 PMC: 11312042. DOI: 10.1016/j.jacadv.2024.100840.